Vaccination against C-terminal region of amyloid-β peptide attenuates plaque deposition in prevention studies

Abstract

The inventors have chosen fragments of the C-terminal part of amyloid-β (Aβ)1-42, which, when administered to a mammal, generate antibodies that specifically target the soluble form of the highly amyloidogenic Aβ1-42. However, it was recently reported that anti-Aβ42 and anti-Aβ40 attenuated plaque deposition in a prevention study, but were less effective in attenuating anti-β-amyloid deposition in therapeutic studies. These data suggest that selective targeting of Aβ42 or Aβ40 might be an effective strategy in preventing amyloid deposition, but may also have limited benefit in a therapeutic setting.

Keywords::

• active immunisation
• amyloid plaques
• antibodies
• C-terminal Aβ1-42
• immunotherapy
• passive immunisation

Patent Details

• Title Interventions for the prevention and/or treatment of amyloid related diseases

• Assignee Curix APS

• Inventors Ole Olesen, Andersen Birkelund, Arne Holm

• Priority date 28/01/2004

• Filing date 28/01/2005

• Publication date 11/08/2005

• Publication no. WO2005072777